title: Predicting 1-month response of macular edema to intravitreal bevacizumab from 1-hour response.
abstract: OBJECTIVE
  To evaluate the clinical significance of the change in central macular thickness (CMT) measured 1 h after intravitreal bevacizumab injection (IVB) for macular edema (ME) secondary to diabetic retinopathy or retinal vein occlusion (RVO).
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  Thirty eyes with ME treated with IVB.
  
  
  METHODS
  A single IVB (1.25 mg/0.5 mL) was administered in 14 eyes with diabetic macular edema (DME) and 16 eyes with ME secondary to RVO. CMT was measured using spectral-domain optical coherence tomography before injection and again 1 hour and 1 month after injection.
  
  
  RESULTS
  Statistically significant CMT reduction was observed at both time points. CMT declined from 542.3 ± 127.7 µm at baseline to 516.9 ± 123.4 µm 1 hour after injection (p < 0.001) and to 345.5 ± 110.0 µm at 1 month after injection (p < 0.001). The reduction in CMT 1 hour after injection was significantly correlated with the reduction in CMT observed at 1 month after injection, with respect to both absolute (r = 0.515, p = 0.004) and relative changes (r = 0.454, p = 0.012). The 15 eyes that had larger 1-hour CMT reductions also showed larger 1-month CMT reductions (242.9 ± 133.8 µm and 43.4% ± 16.5%) when compared with 15 eyes with smaller 1-hour CMT reductions (148 ± 130.6 µm and 25.0% ± 18.3%). This trend was the same for absolute and relative changes (p = 0.037 and 0.008).
  
  
  CONCLUSIONS
  The 1-month response of ME to IVB can be predicted by checking CMT 1 hour after injection.
authors.affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
authors.forename: Dae Joong
authors.initials: DJ
authors.lastname: Ma
authors.affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
authors.forename: Kyu Hyung
authors.initials: KH
authors.lastname: Park
authors.affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: sejoon1@snu.ac.kr.
authors.forename: Se Joon
authors.initials: SJ
authors.lastname: Woo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab